SCHEMBL12373211

SCHEMBL12373211

C=C(C)C(=O)NCCC[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCNC(=O)C(=C)C

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.32
MAPK1 P28482 1/20 0.32
HIF1A Q16665 1/20 0.32
ACHE P22303 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15828189 0.98 KDM4E (0.31) KDM4EMAPK1HIF1AACHE
SCHEMBL15836830 0.94 ACHE (0.38) ACHE
SCHEMBL18176168 0.94
SCHEMBL12094903 0.93 KDM4E (0.34) KDM4EMAPK1HIF1AACHE
SCHEMBL15828198 0.92 ACHE (0.37) ACHE
SCHEMBL16881930 0.92 ACHE (0.37) ACHE
SCHEMBL443374 0.90 KDM4E (0.32) KDM4EMAPK1HIF1AACHE
SCHEMBL26259471 0.88 KDM4E (0.31) KDM4EMAPK1HIF1AACHE
SCHEMBL12222638 0.88 KDM4E (0.38) KDM4EMAPK1HIF1AACHE
SCHEMBL26688049 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873361-B2 Ophthalmic devices BAUSCH + LOMB IRELAND LIMITED (IE) 2024-01-16 US disclosed
US-11829008-B2 Increased stiffness center optic in soft contact lenses for astigmatism correction JOHNSON & JOHNSON VISION CARE, INC. (US) 2023-11-28 US disclosed
US-11754754-B2 Silicone hydrogels comprising N-alkyl methacrylamides and contact lenses made thereof JOHNSON & JOHNSON VISION CARE, INC. (US) 2023-09-12 US disclosed
US-20230244000-A1 MULTIFUNCTIONAL CROSSLINKING AGENTS AND OPHTHALMIC DEVICES FORMED THEREFROM JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2023-08-03 US disclosed
US-20180011223-A1 SILICONE HYDROGELS COMPRISING N-ALKYL METHACRYLAMIDES AND CONTACT LENSES MADE THEREOF JOHNSON & JOHNSON VISION CARE, INC. 2018-01-11 US disclosed
US-20140179867-A1 MONOMER MIXTURES FOR FORMING SILICON HYDROGELS BAUSCH & LOMB INCORPORATED (US) 2014-06-26 US disclosed
US-7994356-B2 Mono ethylenically unsaturated polycarbosiloxane monomers BAUSCH & LOMB INCORPORATED (US) 2011-08-09 US disclosed
US-20110009587-A1 MONO ETHYLENICALLY UNSATURATED POLYCARBOSILOXANE MONOMERS ORAPHARMA, INC. 2011-01-13 US disclosed
US-20110009658-A1 Mono Ethylenically Unsaturated Polycarbosiloxane Monomers BAUSCH HEALTH AMERICAS, INC. 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009658-A1 Mono Ethylenically Unsaturated Polycarbosiloxane Monomers ALOX5, ALOX12, ELOVL5 KDM4E 2360/4885MAPK1 2909/4885HIF1A 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.